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Comparison of Molecular Signatures from Multiple
Skin Diseases Identifies Mechanisms of
Immunopathogenesis
Megan S. Inkeles1, Philip O. Scumpia2, William R. Swindell3, David Lopez1, Rosane M.B. Teles2,
Thomas G. Graeber4, Stephan Meller5, Bernhard Homey5, James T. Elder3,6, Michel Gilliet7,
Robert L. Modlin2,8 and Matteo Pellegrini1
The ability to obtain gene expression profiles from human disease specimens provides an opportunity to identify
relevant gene pathways, but is limited by the absence of data sets spanning a broad range of conditions. Here, we
analyzed publicly available microarray data from 16 diverse skin conditions in order to gain insight into disease
pathogenesis. Unsupervised hierarchical clustering separated samples by disease as well as common cellular and
molecular pathways. Disease-specific signatures were leveraged to build a multi-disease classifier, which
predicted the diagnosis of publicly and prospectively collected expression profiles with 93% accuracy. In one
sample, the molecular classifier differed from the initial clinical diagnosis and correctly predicted the eventual
diagnosis as the clinical presentation evolved. Finally, integration of IFN-regulated gene programs with the skin
database revealed a significant inverse correlation between IFN-b and IFN-g programs across all conditions. Our
study provides an integrative approach to the study of gene signatures from multiple skin conditions, elucidating
mechanisms of disease pathogenesis. In addition, these studies provide a framework for developing tools for
personalized medicine toward the precise prediction, prevention, and treatment of disease on an individual level.
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INTRODUCTION
Gene expression profiling technology, such as microarrays,
provides the opportunity to identify disease-specific genes and
pathways. The NCBI Gene Expression Omnibus (GEO) is a
community resource of publicly available experimental data
sets including those involving human health and disease,
which also incorporates less common diseases studied in
specific laboratories (Edgar et al., 2002). This searchable
database contains annotated gene expression profile data
(both in summarized and raw formats), primarily from
published work. The ability to mine data from GEO provides
a tremendous opportunity for comparing gene expression
profiles across multiple diseases.
Previously, disease profiles have been compared across
multiple data sets by normalizing to controls within each set;
however, this practice limits the use of available data to those
containing equivalent control profiles (Chaussabel et al.,
2008; Wong et al., 2012). To overcome this limitation, data
integration from multiple sources, particularly those from
experiments containing a single disease, can be achieved
with Frozen Robust Multi-array Average (fRMA), which
normalizes samples to a standard reference set of micro-
arrays, eliminating the need for control samples in each data
set (McCall et al., 2010). Here we present a study that uses this
approach on gene expression profiles derived from skin biopsy
specimens. We assembled a database of publicly available
skin microarray samples representing 16 inflammatory,
infectious, and neoplastic conditions. This database was
used to construct a classifier, perform functional analyses to
identify representative pathways, and establish a spectrum of
differentially expressed type I versus type II IFN gene programs
across these diseases (Supplementary Figure S1 online).
RESULTS
Data normalization with frozen RMA
We searched GEO for microarray experiments performed on
human skin samples associated with a dermatological disorder
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(www.ncbi.nlm.nih.gov/geo) (Edgar et al., 2002). Data from
microarray experiments conducted on 311 skin biopsy
samples were downloaded, representing 16 conditions from
15 experiments and 14 laboratories (Supplementary Table S1
online). All samples used the Affymetrix HG U133 Plus 2.0
platform (Santa Clara, CA). To analyze these data as a single
set, fRMA was used to normalize samples such that they
showed comparable probe set intensity distributions (Supple-
mentary Figure S2 online) (McCall et al., 2010).
After unsupervised gene clustering, samples segregate by disease
and into groups with related pathogenesis
In order to determine whether the batch effects within a given
disease were smaller than the differences between diseases,
trees of filtered gene expression profiles were constructed for
both samples and diseases (Figure 1, Supplementary Figure S3
online). Remarkably, we found that in diseases in which there
were multiple batches of microarrays from different sources,
including psoriasis, atopic dermatitis, and leprosy, batches
from the same disease nearly always clustered together,
despite coming from independent data sets (Figure 1). Further-
more, five batches of normal skin, each obtained from healthy
control subjects from different laboratories, clustered together
with little differentiation by batch. However, batch effects
were not completely eliminated as samples from specific
diseases often separated by lab or experiment. There were
isolated cases of individual samples clustering with the
incorrect disease. However, squamous cell carcinoma and
basal cell carcinoma (BCC) samples from a single lab were
split into two groups. Overall, these results suggest that the use
of fRMA allows us to minimize the effect of batch and allows
true disease signatures to predominate.
When the higher-level structure of the tree was examined,
we found that branches of the tree could be annotated as
disease groups with related pathogenesis. These distinct
groups were categorized according to the following descrip-
tions: (i) keratinocyte proliferation and neoplastic growth
(psoriasis and approximately half of the squamous cell
carcinoma and BCC samples), (ii) wound (postoperative
wound, burn), (iii) normal, (iv) allergic (allergic contact
dermatitis, atopic dermatitis), (v) malignant (mycosis fun-
goides, melanoma), and (vi) infectious (leprosy, chancroid).
These relationships are consistent with those seen in an
unrooted disease tree, which was built with one leaf per
disease by averaging distances between all pairs of samples
(Supplementary Figure S3 online).
Proportional median metric for identifying disease-specific gene
signatures
Gene signatures were identified for each disease in order to
build a disease classifier and perform downstream functional
analysis. We developed the ‘‘proportional median’’ (PM)
metric to identify highly expressed gene probe sets for each
disease. The PM of a microarray probe set X in disease Y
represents how highly expressed X was in Y, compared with
all other diseases. Probe sets were ranked by PM for each
disease. Because lowly ranked genes often have low intensity
and tend to be noisier than those with higher ranks,
subsequent analysis utilized genes with high PM values,
reflecting overexpression in a particular disease (Mutch
et al., 2002; Tu et al., 2002). The top 25 genes in the
psoriasis PM list were confirmed by comparison with RNA-
seq data derived from the same samples (Supplementary
Figure S4 online) (Li et al., 2014).
Random forest classifier accurately predicts disease diagnosis
We built a random forest multi-classifier using our disease
expression profiles to predict disease status based on the
expression of a limited number of genes (Breiman, 2001).
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Figure 1. Unsupervised hierarchical clustering tree of 311 skin samples.
Normalized, filtered gene expression profiles were clustered using gene
expression distance (Pearson’s correlation) and displayed in a tree. Each
terminal leaf in the tree represents a biopsy sample and is colored according to
disease, with colored bars to the right representing the majority disease
diagnosis. Samples that clustered apart from other samples of the same
diagnosis can be seen as a leaf that differs in color from its neighbors. Numbers
following disease name labels denote batches of the same disease, and lists of
numbers following a disease name denote multiple batches clustering to the
same tree branch with little or no differentiation by batch. Brackets to the far
right delineate biological groups of neighboring diseases.
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Briefly, the random forest algorithm selects subsets of samples
and genes to iteratively build multiple, parallel decision trees.
This random subsampling and iteration reduce the effect of
noise and outliers on classifier training. In addition, cross-
validation is built into the classifier training process by testing
each decision tree with samples not used to build that tree.
We used PM to select the most informative probe sets as
input to our classifier, which yielded an overall error rate of
4.5% (Supplementary Figure S5 online). Performance for each
disease was assessed by sensitivity, specificity, precision, and
F1 score, a measure of accuracy equivalent to a weighted
average of sensitivity and precision that has values between 0
(poor accuracy) and 1 (perfect accuracy). Sensitivity values
ranged from 0.60 to 1.00 (mean 0.92), and specificity values
ranged from 0.99 to 1.00, which corresponds to an average of
92% of disease samples being accurately classified and 99%
of negative classifications being correct. The range of F1
scores was from 0.75 to 1.00 (mean 0.94) (Supplementary
Table S3 online). We also performed 3-fold cross-validation,
which yielded aggregate F1 scores from 0.75 to 1.00 (mean
0.96) (Supplementary Table S4 online).
To assess the classifier’s ability to generalize, 2-fold cross-
validation with separation by batch was carried out. We
separated data into two approximately equal groups: in
multi-batch conditions (leprosy, psoriasis, atopic dermatitis,
and normal), data were separated according to batch; other-
wise, data were randomly partitioned. Two independent
classifiers were built, each trained on one partitioned set
and tested on the other. PM values used in feature selection
were computed from only one group of data to ensure that test
data did not bias classification. Diseases separated by batch
had F1 scores between 0.90 and 0.95 (mean 0.92), and
diseases randomly separated had F1 scores between 0.71
and 1.00 (mean 0.92), indicating little loss of accuracy with
batch-separated cross-validation (Table 1).
The classifier’s performance was next tested on data not used
for any of the previous analyses, including the feature selection
and training steps of this classifier. We generated 26 de-
identified gene expression profiles derived from biopsy speci-
mens of leprosy, psoriasis, atopic dermatitis, and normal skin.
We also found public data for 168 gene expression profiles
derived from biopsy specimens of psoriasis, atopic dermatitis,
and melanoma (Supplementary Table S5 online). The classifier
was used to assess these 194 validation samples, yielding an
overall sensitivity of 0.93, specificity of 0.99, and F1 statistics
between 0.76 and 1.0 (Supplementary Table S6 online).
Upon follow-up of the patients from whom we had
collected samples, we discovered that one who was clinically
diagnosed with atopic dermatitis, which we classified as
psoriasis, had an unusual presentation. This patient had a
history of an atopic diathesis including hay fever, increased
total IgE levels, as well as elevated levels of the eosinophilic
cationic protein. The patient presented clinically with chronic
dermatitis on the palms and soles. Furthermore, inflammatory
skin lesions on the arms and other locations were clinically
diagnosed as atopic dermatitis, and a sample was obtained for
the present study. However, later the patient developed
inflammatory plaques on the lower back, which were
clinically diagnosed as psoriasis. Both atopic dermatitis and
psoriasis were considered as a diagnosis for this patient at
various stages; however, the co-occurrence of atopic derma-
titis and psoriasis is rare, perhaps because of the opposing
immunopathogenic mechanisms for the two diseases (Beer
et al., 1992; Henseler and Christophers, 1995; Eyerich et al.,
2011). Although we cannot be certain of the initial diagnosis,
our molecular classifier correctly predicted the diagnosis as
the clinical course evolved.
Functional annotation of related disease signatures using
cell-type–specific deconvolution and k-means clustering shows
shared and unique mechanisms of disease
We investigated whether diseases that grouped together on the
hierarchical clustering tree shared cell types in their associated
lesions. Using cell-type–specific gene signatures developed in
a previous work by Swindell et al., the relative enrichment of
each cell-type signature was assessed in each disease and
subjected to hierarchical clustering using Euclidian distance
(Figure 2) (Swindell et al., 2012; Swindell et al., 2013).
In some instances, the clustering by cell-type signatures was
consistent with the hierarchical clustering and unrooted trees
generated from the entire filtered gene profiles (Figure 1,
Supplementary Figure S3 online). For example, atopic derma-
titis, allergic contact dermatitis, and normal skin clustered
together in both trees, and deconvolution analysis revealed a
T-regulatory cell gene signature consistent with previous
studies of atopic dermatitis expression profiles (Figure 2)
(Clark and Kupper, 2007; Hanafusa et al., 2013). The
notable absence of a general T-cell–specific signature in
psoriasis and atopic dermatitis likely reflects that expression
Table 1. Two-fold cross-validation of random forest
classifier, with separation by batch where applicable
Condition Sensitivity Specificity Precision F1
Leprosy1 0.86 1.00 0.97 0.91
Psoriasis1 0.96 0.97 0.94 0.95
Chancroid 1.00 1.00 1.00 1.00
Allergic contact dermatitis 0.78 1.00 1.00 0.88
Irritant contact dermatitis 1.00 1.00 1.00 1.00
Atopic dermatitis1 0.95 0.99 0.88 0.91
Burn 1.00 1.00 1.00 1.00
Acute wound 0.83 1.00 1.00 0.91
Postoperative wound 1.00 1.00 1.00 1.00
Mycosis fungoides 1.00 1.00 1.00 1.00
Basal cell carcinoma 0.87 1.00 0.93 0.90
Melanoma 0.86 0.98 0.67 0.75
Squamous cell carcinoma 0.60 1.00 0.86 0.71
Sarcoidosis 1.00 1.00 1.00 1.00
Stevens–Johnson syndrome 0.80 1.00 1.00 0.89
Normal skin1 0.96 0.98 0.84 0.90
1Denotes diseases separated by batch.
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of T-cell–specific genes is much greater in conditions such as
mycosis fungoides and Stevens–Johnson syndrome, which are
characterized by marked T-cell activation and proliferation
(Nassif et al., 2004; Chung et al., 2008; Yamashita et al.,
2012). In other instances, the clustering differed by cell type
versus hierarchical clustering, suggesting that other factors
must be involved in the observed groupings.
We used pathway analysis of gene signatures to further
investigate common pathways within each disease group. For
each group of diseases indicated by hierarchical clustering,
combined gene signatures were constructed and evaluated for
enriched functional terms. K-means clustering was performed
on the P-values associated with each term (Figure 3). Sig-
nificantly enriched terms support previous findings in the
literature: allergic diseases were enriched for ‘‘cell–cell adhe-
rens junction’’ (P-value¼ 8.9310 3), and hyperprolifera-
tive/neoplastic diseases were enriched for ‘‘keratinocyte
and epithelial cell development’’ (P-value¼2.47109)
(O’Regan et al., 2008; Cai et al., 2012). Wound, malignant,
and infectious groups share overlapping-enriched GO terms,
associated with response to wounding.
Functional analysis of PM signatures shows enrichment for genes
and pathways corresponding to single diseases
In order to assess the relevance of individual disease PM
signatures, additional pathway analysis was performed
on the 250 probe sets with the highest PM values for each
disease. DAVID and Ingenuity Pathways functional analyses of
individual disease signatures often showed a correspondence
to the disease of origin (Supplementary Tables S7 and S8
online). For example, Ingenuity analysis of the melanoma PM
signature revealed an enrichment of ‘‘biologic functions’’
relevant to melanocyte development and disorders (‘‘differ-
entiation of melanocytes,’’ P-value¼ 4.41009), as well as
significant enrichment of the ‘‘Melanocyte Development and
Pigmentation Signaling canonical pathway’’ (P-value¼ 9.2
 1005) (Figure 4c). We developed a web-based visualiza-
tion tool (http://pathways-pellegrini.mcdb.ucla.edu/goTeles/
dot_plot.html) that plots the expression of a gene within our
database; shown are two melanocyte development genes
(Figure 4a and b).
Network analysis of the PM signatures was carried out using
Ingenuity Pathways analysis to visualize connected genes and
pathways in each disease and further evaluate the functional
significance of our signatures. Notably, a psoriasis network
showed connections between TCN1, OASL, and SPRR3
(Supplementary Figure S6 online). This network appears to
provide a cellular nexus connecting key pathogenesis ele-
ments, including differentiation-associated pathways, IFN-
directed responses, and infiltrating inflammatory cells such
as neutrophils. Furthermore, cell-type–specific deconvolution
of the psoriasis PM signature demonstrated expression patterns
consistent with the presence of neutrophils (Supplementary
Figure S7 online) (Fujimoto et al., 1997; Yao et al., 2008;
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Figure 2. Cell-type–specific signature enrichment. For each of 24 cell-type–specific signatures, log fold changes were calculated using average gene expression
for each condition. Each fold change represents the enrichment for a particular cell type in that condition relative to the other 15 conditions. Enrichment profiles for
each condition were clustered using Euclidean distance and displayed in a heatmap, where rows correspond to conditions and columns correspond to cell types.
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Sua´rez-Farin˜as et al., 2011; Sua´rez-Farin˜as et al., 2012;
Swindell et al., 2013).
Type I versus type II IFN gene programs have a negative inverse
correlation across a spectrum of skin diseases
Type I and type II IFNs have opposing immunoregulatory roles
in human disease, and previous work has shown different
diseases or subtypes of disease exhibiting a range of IFN
responses. Recent work in leprosy has demonstrated a distinct
pattern of T helper type 1 (Th1) versus Th2 cytokines, which
we have used as a model for interrogating our skin disease
database in order to identify similar patterns across a range of
conditions (Yamamura et al., 1991; Wong et al., 2012; Teles
et al., 2013). IFN-g (type II IFN) is involved in macrophage
activation to fight bacterial infection and is opposed by IFN-a/b
(type I IFN), which combats viral infection. Because IFNs are
weakly detected on microarrays, we used type I– and type II–
specific induced transcriptional profiles of human peripheral
blood mononuclear cells to infer the expression of IFN
signatures (Waddell et al., 2010; Teles et al., 2013).
Integration of the IFN gene expression profiles with our data
set containing 16 different skin conditions demonstrated a
significant, inverse correlation between IFN-b- and IFN-g-
regulated genes across all skin diseases studied (r¼ 0.66,
P-value¼0.006), underscoring the opposing roles of IFN-b
and IFN-g in skin disease (Figure 5). The Stevens–Johnson
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Figure 3. Functional annotation and k-means clustering of group signatures. Proportional median (PM) signatures for each biological group from unsupervised
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syndrome samples, which were obtained from blister fluid
rather than from full-thickness biopsies, had the most extreme
IFN-b IFN-g profiles. Nevertheless, even if these samples were
omitted, the anti-correlation between IFN-b and IFN-g profiles
was still significant (r¼  0.53, P-value¼ 0.04).
DISCUSSION
Insights into disease pathogenesis obtained by comparison of
gene expression profiles are often limited because these com-
parisons are performed either between two different diseases
or between one disease and healthy controls, and therefore
cannot identify distinct and common mechanisms of patho-
genesis. Here, we performed a cross-disease analysis of
molecular profiles from multiple skin diseases. Using fRMA,
it was possible to assemble a database of gene expression
profiles from 311 samples spanning 16 conditions and
visualize disease relationships on a hierarchical clustering
tree. Remarkably, we found that samples of a particular
disease that were taken from different batches colocalized to
the same branch. This was particularly striking in the case of
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Figure 4. Visualization of melanoma proportional median (PM) signature. (a, b) Visualization of normalized intensities for representative probe sets of
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normal skin, where five batches of samples taken from healthy
control subjects not only clustered on the same branch but
were arranged with little differentiation by batch.
Our approach demonstrates that a multi-disease classifier
can be built from disparate public data sources comprising
over a dozen different conditions in a single tissue. We built
this classifier from disease-specific gene signatures and
found that it was accurate and robust to batch effect. The
potential utility of molecular classification over the classic
clinical criteria was demonstrated by the correct classification
of an ambiguous case of psoriasis. A multi-disease classifier
using epithelial cells from patients with psoriasis, atopic
dermatitis, allergic contact dermatitis, and irritant contact
dermatitis was previously constructed, although this was
limited to diseases that had epidermal involvement
(Kamsteeg et al., 2010). Our work expands this principle to
a wide range of both inflammatory and neoplastic diseases
and demonstrates the potential value of this approach in
comparing diverse conditions. This approach can be
expanded to include a more diverse spectrum of diseases, as
more data are publicly available, allowing for the comparative
study of diseases for which skin biopsy specimens may not be
widely available.
We also analyzed these data by three supervised
approaches: analysis of cell-type signatures, Gene Ontology
pathway enrichment, and IFN response signatures. Together,
these bioinformatic analyses provided insight into the distinct
and related pathogenesis of the diseases. For example,
hierarchical clustering of gene expression profiles revealed
that leprosy and chancroid were located on the same branch,
which we termed ‘‘infectious’’ on the basis of their known
etiologies. In the deconvolution analysis of cell-type signa-
tures, both diseases were characterized by the enrichment of
similar lymphoid (CD3þ , CD4þ , CD8þ , regulatory T cells,
and B cells) and myeloid (monocytes, macrophages, dendritic
cells, and neutrophils) expression profiles. Furthermore, Gene
Ontology enrichment analysis identified the terms ‘‘lyso-
some’’, ‘‘T-cell differentiation’’, and ‘‘leukocyte adhesion’’.
In addition, we found an anti-correlation of type I and type II
IFN responses across a wide range of skin diseases of different
etiologies, consistent with our previous studies using leprosy
as a model (Teles et al., 2013). An earlier multi-disease
comparison found that the magnitude of an IFN gene
signature distinguished different inflammatory skin diseases
but could not distinguish between the type I and type II IFN
patterns (Wong et al., 2012).
The present findings provide a rationale for further investi-
gations to determine how these different IFN programs con-
tribute to the pathogenesis of these diseases and identify
treatment targets. The spectrum of IFN-b versus IFN-g gene
program expression in the skin diseases studied here is
consistent with current practices in the treatment of skin
disease. Typically, type I IFN exhibits anti-proliferative effects,
and is used to treat neoplasms, such as melanoma and BCC,
which have a negative type I IFN score. It should be noted that
IFN-g has been used to treat acute atopic dermatitis, even
though chronic atopic dermatitis lesions, as studied here,
express IFN-g consistent with our findings (Grewe et al., 1994;
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Figure 5. Type I and type II IFN program cross-regulation. IFN-b and IFN-g scores were calculated by ranking genes specifically regulated by IFN-b or IFN-g
relative to total gene expression and centering relative to the mean rank of each gene across all conditions. Individual up- or downregulated scores for each type of
IFN were obtained by summing centered ranks, and an overall IFN score was obtained by subtracting the upregulated sum of ranks by the downregulated sum of
ranks. Intuitively, high scores for each type of IFN represent high expression of IFN-stimulated genes, low expression of IFN-repressed genes, or both, such that
placement on each axis shows the magnitude of expression of IFN-b or IFN-g gene programs. The plot shows a significant negative inverse correlation (r¼ 0.66,
P-value¼ 0.006). Removing the outlier Stevens–Johnson syndrome, the correlation remains significant (r¼ 0.53, P-value¼ 0.04).
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Hamid et al., 1994; Grewe et al., 1995; Grassegger and Ho¨pfl,
2004; Alazemi and Campos, 2006). Anti-IFN-g has also been
shown in preliminary studies to have a positive effect on Th1-
mediated autoimmune skin diseases, including psoriasis,
which we found had a high type II IFN score (Skurkovich
and Skurkovich, 2006).
High-throughput analysis of gene expression profiles is a
step toward the development of tools for personalized med-
icine. These studies have led to the discovery of individual
genes and pathways that underlie disease pathology, which
can be leveraged as biomarkers to diagnose and predict the
course of disease, as well as identify targets for therapeutic
intervention. For example, HLA allele type has been linked to
adverse responses to commonly used drugs such as the anti-
retroviral abacavir and the anti-epileptic carbamazepine (Illing
et al., 2013). Subsequent diagnostic tests would be based on
such individual genes or sets of genes, making them more
economical for clinical use. The integrative molecular
classification and functional analysis of multiple skin
conditions reported here demonstrates the value of such a
comparison to gain insight into the pathogenesis of human
disease.
MATERIALS AND METHODS
Microarray acquisition, processing, and clustering
Data were obtained from the NCBI GEO as described in
Supplementary Methods and Supplementary Table S1 online (http://
www.ncbi.nlm.nih.gov/geo/) (Edgar et al., 2002). Additional
validation samples were obtained with written informed consent
from de-identified biopsy specimens as described in the supple-
ment and Supplementary Table S5 online. Data were normalized
using the fRMA method and filtered by a mean intensity of at least
15 in any disease. Unsupervised hierarchical clustering was used to
group the normalized, filtered expression profiles using Pearson’s
correlation.
PM
Probe sets were ranked using the PM, which we define as the median
intensity of a probe set within one disease divided by the median
intensity of the same probe set across all samples. For each disease,
probe sets were ranked in descending order by PM.
Random forest classifier
A random forest classifier was built using the Matlab TreeBagger
class (see Supplementary Methods for full description). The classifier
feature space was reduced by selecting the 25 probe sets with the
highest PM values across the training set for each disease. Classifier
validation was performed in three ways: 3-fold cross-validation, 2-
fold cross-validation with separation by experimental batch where
applicable, and external validation using independent samples.
Pathway analysis
The 250 probe sets with the highest PM value for each disease were
selected for pathway analysis using Ingenuity Pathways analysis
(http://www.ingenuity.com) and DAVID Functional Annotation
Analysis (http://david.abcc.ncifcrf.gov/), using the top 250 probe
sets by PM from each disease signature (Huang et al., 2009a, b;
www.ingenuity.com).
Cell-type–specific signature enrichment
Cell-type–specific expression profiles for 24 cell types were calcu-
lated as previously described and are described in more detail in the
Supplementary Methods (Swindell et al., 2013).
Group signatures
PM values were calculated for five disease group signatures, based on
hierarchical clustering, and Gene Ontology enrichment was performed
for each group (see Supplementary Methods online for details).
IFN profile integration
IFN-b and IFN-g-specific scores were calculated by adapting a
previously described method (see Supplementary Methods for details)
(Teles et al., 2013).
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